A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2018
This article has no abstract
Epistemonikos ID: 1829ef2887e11eb15743ad383bbf1fd4ae7c5b72
First added on: Apr 07, 2025